Arix Bioscience Share Chat (ARIX)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Arix Bioscience	LSE:ARIX	London	Ordinary Share	GB00BD045071	ORD 0.001P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	176.50p	173.00p	180.00p	176.50p	176.50p	176.50p	23,927	08:00:00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.6	-9.5	-0.4	-	237.96

Arix Bioscience Share Discussion Threads

Showing 51 to 75 of 75 messages

Chat Pages: 3 2 1

Date	Subject	Author	Discuss
14/9/2018 14:01	Looks like a pretty impressive Board appt...	skyship	Read Full Thread Reply
21/8/2018 15:32	Have doubled my holding with one buy at 158.50 and one at 172.	chesil356	Read Full Thread Reply
21/8/2018 13:19	Bought this morning at 1.63 The Proactive interview is very good. See www.proactiveinvestors.co.uk/companies/stocktube/10188/artios-in-strong-position-to-accelerate-cancer-programmes-after-arix-investment-10188.html	brexitplus	Read Full Thread Reply
21/8/2018 11:57	Nice to see this edging back up. There was comment yesterday including two broker forecasts of 253p and 314p. hxxp://www.proactiveinvestors.co.uk/companies/news/203218/arix-bioscience-share-sale-explains-recent-market-disconnect-say-brokers-203218.html	pdt	Read Full Thread Reply
21/8/2018 08:38	Can't even buy £500 worth of these online and market makers buying above the bid.Looks like they are now short of stock to sell.	chesil356	Read Full Thread Reply
18/8/2018 21:57	what about directors /management COMP running at circa £5m pa? That's £50m over the next 10 years for a market cap business of only £200+ Seems an outrageous level of remuneration.....	kristini2	Read Full Thread Reply
17/8/2018 20:13	A new interview on Proactive site explaining reasons behind investment in Artios, worth a listen; hxxp://www.proactiveinvestors.co.uk/companies/stocktube/10165/arix-sees-significant-potential-as-it-ups-stake-in-cancer-treatment-developer-artios-10165.html Syncona are trading above NAV and we are considerably below NAV. With the Seller seemingly done for a while these will hopefully rise back to the 200p area I would have thought. However, nothing surprises me any more! Rambutan2 - ha, ha PDT are just my initials!	pdt	Read Full Thread Reply
17/8/2018 14:16	PDT (prelude trust?), that's a good spot on Artios.	rambutan2	Read Full Thread Reply
17/8/2018 14:15	Yes, that overhang is almost certainly the reason and I'd expect to start heading north from here before too long: LONDON, 17 August 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, was notified today that Christopher Chipperton has today sold 3,000,000 ordinary shares of GBP 0.00001 nominal value each ("Ordinary Shares") at a price of 155 pence per Ordinary Share (the "Disposal"). As a result of the Disposal Christopher Chipperton is interested, in aggregate, in 7,147,914 Ordinary Shares in the Company representing 5.3 per cent. of the Company's issued share capital. Christopher Chipperton (the "Locked-in Party") has entered into a lock-in agreement (the "Agreement") pursuant to which he shall not dispose of any interest in Ordinary Shares (held directly or indirectly) for a period of 12 months following the Disposal, save in certain very limited circumstances. The Agreement also provides that, save in certain limited circumstances, the Locked-in Party shall not dispose of any interest in Ordinary Shares (held directly or indirectly) for a period of 12 months following the first anniversary of the Disposal unless such disposal is effected through Stifel Nicolaus Europe Limited ("Stifel"), in order to ensure an orderly market in the Ordinary Shares ("Orderly Market Period"). Any disposal of Ordinary Shares during the Orderly Market Period will be in such a manner as Stifel may reasonably require with the view to the maintenance of an orderly market.	rambutan2	Read Full Thread Reply
17/8/2018 13:16	Does today's news of a 3m share sale explain the recent decline in the share price? On a separate note I saw a positive article on the work being undertaken by Artios in today's Daily Mail; hTTp://www.dailymail.co.uk/news/article-6068949/New-cancer-pill-stops-tumor-cells-repairing-making-sensitive-radiotherapy.html	pdt	Read Full Thread Reply
17/8/2018 09:50	I had a top up at 157p this morning although it shows on here as a Sell on the trade list. There does seem to be a disconnect between NAV and the market cap.	pdt	Read Full Thread Reply
16/8/2018 21:06	AUTL closes at $30 today. So stake value is £74m. At 158p close, ARIX mkt cap is £215m. So AUTL currently constitutes a third of mkt cap. Chuck in the approx £120m of cash and £7m (as at close) in ITRM, and that's leaving very little value put on everything else owned.	rambutan2	Read Full Thread Reply
11/8/2018 08:20	I see Autolus was up 8% on friday and has been rising over the last 3 weeks. I added to my small holding here at the end of last week. Feel confident that this will get back to 200p plus at some point over the next 18 months so happy to be patient.	pdt	Read Full Thread Reply
10/8/2018 19:40	I see what you mean, this level of comp for a business of this size and level of development appear excessive...........	kristini2	Read Full Thread Reply
10/8/2018 02:56	Re ITRM: “We are delighted to begin our first Phase 3 clinical trial for sulopenem early in the third quarter, consistent with our prior guidance. The commencement of our Phase 3 program marks an important milestone for our company,” said Corey Fishman, Chief Executive Officer of Iterum. “We are leveraging our prior clinical trial data, and the important feedback we received from the FDA and European regulators, to conduct our Phase 3 trials, with data expected to readout in the second half of 2019. If approved, oral sulopenem would be the first new drug approved for uncomplicated UTIs in over 20 years and would provide a much-needed treatment option in a large and growing market.” http://uk.advfn.com/stock-market/NASDAQ/ITRM/share-news/Iterum-Initiates-SURE-1-a-Phase-3-Clinical-Trial/78045894	rambutan2	Read Full Thread Reply
10/8/2018 02:49	kristini2, see pages 60-64 of the annual report below. But suffice to say, the execs are clearly believers in the greed is good maxim! httPs://arixbioscience.com/wp-content/uploads/2018/04/Arix-Bioscience-AR2017-FINAL-web.pdf	rambutan2	Read Full Thread Reply
09/8/2018 13:30	Ram what are the annual salaries being taken here do you know? K	kristini2	Read Full Thread Reply
07/8/2018 19:19	My very approx back of the envelope calc says that for £230m mkt cap you are getting: £60m in AUTL £74m in 13 other interesting companies, 3 of which are listed. £120m cash A highly experienced, albeit highly expensive board/management team.	rambutan2	Read Full Thread Reply
07/8/2018 18:58	I wonder whether under pressure Woodford are dripping out a few, along with private investors (supposedly 4000 of them) who bought in at ipo and are now bored.	rambutan2	Read Full Thread Reply
07/8/2018 16:43	I have just bought my first holding here. Attracted by the Pharmaxis investment. I was considering buying Pharmaxis direct but this way I have spread the risk. Why is it trading below NAV ? The management seem experienced and well connected and a nice spread of investments.	pdt	Read Full Thread Reply
06/8/2018 17:56	Undervalued? hxxp://www.proactiveinvestors.co.uk/companies/news/202119/arix-biosciences-progress-significantly-undervalued-suggests-us-broker-202119.html	alcimedes	Read Full Thread Reply
06/8/2018 14:32	First VIPE and looks interesting: hTtp://www.pharmaxis.com.au/assets/Documents/pdf/02018/ASX/2018-08-06-PXS-Placement-Announcement-FINAL.pdf htTp://www.pharmaxis.com.au/	rambutan2	Read Full Thread Reply
01/8/2018 20:00	Half year nav was 191p. Not sure why ARIX is now trading at a discount, but gritted my teeth and bought a few at 174p today. (For ref, edison ipo initiation note: https://www.edisoninvestmentresearch.com/research/report/arix-bioscience/preview/ )	rambutan2	Read Full Thread Reply
01/8/2018 19:50	Whilst even more recent IPO Autolus stays well above $17 listing price: http://uk.advfn.com/p.php?pid=quote&symbol=autl Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes that its largest Group Business holding Autolus Therapeutics plc ("Autolus") has today announced the closing of its previously announced initial public offering ("IPO") in the United States of 10,147,059 American Depositary Shares ("ADSs"), representing 10,147,059 ordinary shares, at an initial public offering price of $17.00 per ADS, which includes an additional 1,323,529 ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs. All of the ADSs were offered by Autolus. Following the IPO, Arix retains a stake of 7.9% in Autolus (amounting to 3,161,533 ordinary shares), which was valued at $82.8m (GBP62.4m)[1] at the close of business on 25 June 2018. So, at today's $24, the stake is worth £59m.	rambutan2	Read Full Thread Reply
01/8/2018 19:46	Recent IPO Iterum struggling a bit at mo, but very early days: http://uk.advfn.com/p.php?pid=quote&symbol=itrm Arix Bioscience plc ("Arix", LSE: ARIX) a global healthcare and life science company supporting medical innovation, today (May 30) notes that its Group Business Iterum Therapeutics plc ("Iterum", NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, today closed its initial public offering of 6,150,000 of its ordinary shares at an initial offering price to the public of $13.00 per share. All of the shares were offered by Iterum. The shares are listed for trading on the Nasdaq Global Market under the symbol "ITRM". Arix has invested $4.4 million (GBP3.3 million) in Iterum's IPO. Following completion of the offering, Arix holds a stake of approximately 7.4 percent of the issued and outstanding shares of Iterum (amounting to 1,031,903 ordinary shares). Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: "Iterum was founded in 2015 with the ambition to develop an antibiotic that addresses the growing crisis of multi-drug-resistant pathogens, and today we see it reach an important milestone towards reaching that goal. We believe Iterum has considerable potential to deliver important new treatment options to patients and we are excited to support the company's next stage of growth and development."	rambutan2	Read Full Thread Reply

Chat Pages: 3 2 1

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.